|
This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or
standards of non-Merck sources.
Pronunciation
(lor A ze pam)
Generic Available (U.S.)
Yes
Controlled Substance
C-IV
Brand Names: U.S.
Brand Names: Canada
Pharmacologic Category
Use: Labeled Indications
Oral: Management of anxiety disorders or short-term (≤4 months) relief of the symptoms of anxiety, anxiety associated with depressive symptoms, or insomnia due to anxiety or transient stress
I.V.: Status epilepticus, amnesia, sedation
Use: Dental
Short-term relief of anxiety prior to dental appointment
Use: Unlabeled
Ethanol detoxification; psychogenic catatonia; partial complex seizures; agitation (I.V.); antiemetic for chemotherapy; rapid tranquilization of the agitated patient
Pregnancy Risk Factor
D
Pregnancy Considerations
Teratogenic effects have been observed in some animal studies. Lorazepam and its metabolite cross the human placenta. Teratogenic effects in humans have been observed with some benzodiazepines (including lorazepam); however, additional studies are needed. The incidence of premature birth and low birth weights may be increased following maternal use of benzodiazepines; hypoglycemia and respiratory problems in the neonate may occur following exposure late in pregnancy. Neonatal withdrawal symptoms may occur within days to weeks after birth and “floppy infant syndrome” (which also includes withdrawal symptoms) have been reported with some benzodiazepines (including lorazepam). Elimination of lorazepam in the newborn infant is slow; following in utero exposure, term infants may excrete lorazepam for up to 8 days.
Lactation
Enters breast milk/not recommended (AAP rates “of concern”; AAP 2001 update pending)
Breast-Feeding Considerations
Drowsiness, lethargy, or weight loss in nursing infants have been observed in case reports following maternal use of some benzodiazepines.
Contraindications
Hypersensitivity to lorazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist); acute narrow-angle glaucoma; sleep apnea (parenteral); intra-arterial injection of parenteral formulation; severe respiratory insufficiency (except during mechanical ventilation)
Warnings/Precautions
Concerns related to adverse effects:
• Anterograde amnesia: Benzodiazepines have been associated with anterograde amnesia.
• CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).
• Paradoxical reactions: Paradoxical reactions, including hyperactive or aggressive behavior, have been reported with benzodiazepines, particularly in adolescent/pediatric or psychiatric patients.
Disease-related concerns:
• Drug abuse: Use with caution in patients with a history of drug abuse, alcoholism, or significant personality disorders; potential for drug dependency exists. Tolerance, psychological and physical dependence may occur with prolonged use. Risk of dependence increases with higher dosage and longer duration of therapy.
• Hepatic impairment: Use with caution in patients with hepatic impairment. Dose adjustment may be needed. May worsen hepatic encephalopathy.
• Impaired gag reflex: Use with caution in patients with an impaired gag reflex.
• Psychiatric disorders: Use caution in patients with depression, particularly if suicidal risk may be present. Pre-existing depression may emerge or worsen during therapy. Not recommended for use in primary depressive or psychotic disorders.
• Renal impairment: Use with caution in patients with renal impairment.
• Respiratory disease: Use with caution in patients with respiratory disease, including COPD or sleep apnea. Benzodiazepines may cause significant respiratory depression.
Concurrent drug therapy issues:
• CNS depressants/psychoactive medications: Use with caution in patients receiving other CNS depressants or psychoactive medication; effects with other sedative drugs or ethanol may be potentiated.
Special populations:
• Debilitated patients: Use with caution in debilitated patients; initial doses should be at the lower end of dosing range.
• Elderly: Due to increased sensitivity in this age group, smaller doses of benzodiazepines may be safer and as effective. Avoid using doses >3 mg daily of lorazepam (Beers Criteria).
• Fall risk: Use with extreme caution in patients who are at risk of falls; benzodiazepines have been associated with falls and traumatic injury.
Dosage form specific issues:
• Benzyl alcohol: Some products may contain benzyl alcohol which has been associated with "gasping syndrome" in neonates.
• Polyethylene glycol: Parenteral formulation contains polyethylene glycol. May be associated with toxicity in high-dose and/or longer-term therapy.
• Propylene glycol: Parenteral formulation contains propylene glycol (PG). May be associated with dose-related toxicity and can occur ≥48 hours after initiation of lorazepam. Limited data suggest increased risk of PG accumulation at doses of ≥6 mg/hour for 48 hours or more (Nelson, 2008). Consider monitoring for signs of toxicity which may include acute renal failure, lactic acidosis, and/or osmol gap. In high-risk patients requiring higher doses/extended treatment durations, use of enteral delivery of lorazepam tablets may be beneficial (Jacobi, 2002).
Other warnings/precautions:
• Appropriate use: Does not have analgesic, antidepressant, or antipsychotic properties.
• Hypnotic: Appropriate use: As a hypnotic, should be used only after evaluation of potential causes of sleep disturbance. Failure of sleep disturbance to resolve after 7-10 days may indicate psychiatric or medical illness. A worsening of insomnia or the emergence of new abnormalities of thought or behavior may represent unrecognized psychiatric or medical illness and requires immediate and careful evaluation.
• Withdrawal: Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose. Use caution when reducing dose or withdrawing therapy; decrease slowly and monitor for withdrawal symptoms. Flumazenil may cause acute withdrawal in patients receiving long-term benzodiazepine therapy.
Adverse Reactions
>10%:
Central nervous system: Sedation
Respiratory: Respiratory depression
1% to 10%:
Cardiovascular: Hypotension
Central nervous system: Akathisia, amnesia, ataxia, confusion, depression, disorientation, dizziness, headache
Dermatologic: Dermatitis, rash
Gastrointestinal: Changes in appetite, nausea, weight gain/loss
Neuromuscular & skeletal: Weakness
Ocular: Visual disturbances
Respiratory: Apnea, hyperventilation, nasal congestion
<1% or frequency not defined: Asthenia, blood dyscrasias, disinhibition, euphoria, fatigue, increased salivation, menstrual irregularities, physical and psychological dependence (with prolonged use), reflex slowing, polyethylene glycol or propylene glycol poisoning (prolonged I.V. infusion), suicidal ideation, seizure, vertigo
Metabolism/Transport Effects
None known.
Drug Interactions
Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl). Risk C: Monitor therapy
CloZAPine: Benzodiazepines may enhance the adverse/toxic effect of CloZAPine. Management: Consider decreasing the dose of (or possibly discontinuing) benzodiazepines prior to initiating clozapine. Risk D: Consider therapy modification
CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. Exceptions: Levocabastine (Nasal). Risk C: Monitor therapy
Divalproex: May decrease the metabolism of LORazepam. Risk D: Consider therapy modification
Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use. Risk D: Consider therapy modification
Fosphenytoin: Benzodiazepines may increase the serum concentration of Fosphenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Risk C: Monitor therapy
HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Risk C: Monitor therapy
Loxapine: May enhance the adverse/toxic effect of LORazepam. Specifically, prolonged stupor, respiratory depression, and/or hypotension. Risk C: Monitor therapy
Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants. Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established. Risk D: Consider therapy modification
OLANZapine: May enhance the adverse/toxic effect of Benzodiazepines. Management: Avoid concomitant use of parenteral benzodiazepines and IM olanzapine due to risks of additive adverse events (e.g., cardiorespiratory depression). Olanzapine prescribing information provides no specific recommendations regarding oral administration. Risk X: Avoid combination
Phenytoin: Benzodiazepines may increase the serum concentration of Phenytoin. Short-term exposure to benzodiazepines may not present as much risk as chronic therapy. Risk C: Monitor therapy
Probenecid: May increase the serum concentration of LORazepam. Risk D: Consider therapy modification
Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Risk C: Monitor therapy
Theophylline Derivatives: May diminish the therapeutic effect of Benzodiazepines. Risk D: Consider therapy modification
Valproic Acid: May decrease the metabolism of LORazepam. Risk D: Consider therapy modification
Yohimbine: May diminish the therapeutic effect of Antianxiety Agents. Risk C: Monitor therapy
Ethanol/Nutrition/Herb Interactions
Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.
Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).
Storage
I.V.: Intact vials should be refrigerated. Protect from light. Do not use discolored or precipitate-containing solutions. May be stored at room temperature for up to 3 months [data on file (Hospira Inc, 2010)]. Parenteral admixture is stable at room temperature (25°C) for 24 hours.
Tablet: Store at room temperature.
Reconstitution
Injection: Dilute with equal volume of compatible diluent (D5W, NS, SWFI).
Infusion: Use 2 mg/mL injectable vial to prepare; there may be decreased stability when using 4 mg/mL vial. Dilute ≤1 mg/mL and mix in glass bottle. Precipitation may develop. Can also be administered undiluted via infusion.
Compatibility
Variable stability (consult detailed reference) in D5W, LR, NS.
Y-site administration: Compatible: Acetaminophen, acyclovir, albumin, allopurinol, amifostine, amikacin, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, anakinra, atracurium, bivalirudin, bumetanide, caspofungin, cefepime, cefotaxime, ciprofloxacin, cisatracurium, cisplatin, cladribine, clonidine, cyclophosphamide, cytarabine, dexamethasone sodium phosphate, dexmedetomidine, diltiazem, dobutamine, docetaxel, dopamine, doripenem, doxorubicin, doxorubicin liposome, epinephrine, erythromycin lactobionate, etomidate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, fosphenytoin, furosemide, gemcitabine, gentamicin, granisetron, haloperidol, heparin, hetastarch in lactated electrolyte injection (Hextend®), hydrocortisone sodium succinate, hydromorphone, labetalol, levofloxacin, linezolid, melphalan, methadone, methotrexate, metronidazole, micafungin, midazolam, milrinone, morphine, nicardipine, nitroglycerin, norepinephrine, oxaliplatin, paclitaxel, palonosetron, pancuronium, pemetrexed, piperacillin, piperacillin/tazobactam, potassium chloride, ranitidine, remifentanil, sulfamethoxazole/trimethoprim, tacrolimus, teniposide, thiotepa, vancomycin, vecuronium, vinorelbine, zidovudine. Incompatible: Aldesleukin, aztreonam, caffeine citrate, floxacillin, gallium nitrate, idarubicin, imipenem/cilastatin, ondansetron, pantoprazole, sargramostim, sufentanil. Variable (consult detailed reference): Foscarnet, propofol, thiopental.
Compatibility in syringe: Compatible: Aripiprazole, cimetidine, dimenhydrinate, haloperidol, hydromorphone. Incompatible: Caffeine citrate, pantoprazole, sufentanil. Variable (consult detailed reference): Ranitidine.
Mechanism of Action
Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.
Pharmacodynamics/Kinetics
Onset of action:
Hypnosis: I.M.: 20-30 minutes
Sedation: I.V.: 5-20 minutes
Anticonvulsant: I.V.: 5 minutes, oral: 30-60 minutes
Duration: 6-8 hours
Absorption: Oral, I.M.: Prompt
Distribution: Vd: Neonates: 0.76 L/kg, Adults: 1.3 L/kg
Protein binding: 85%; free fraction may be significantly higher in elderly
Metabolism: Hepatic to inactive compounds
Bioavailability: Oral: 90%
Half-life elimination: Neonates: 40.2 hours; Older children: 10.5 hours; Adults: 12.9 hours; Elderly: 15.9 hours; End-stage renal disease: 32-70 hours
Time to peak: Oral: 2 hours
Excretion: Urine; feces (minimal)
Dosage
Antiemetic (unlabeled use):
Children 2-15 years: I.V.: 0.05 mg/kg (up to 2 mg/dose) prior to chemotherapy
Adults: Oral, I.V. (Note: May be administered sublingually; not a labeled route): 0.5-2 mg every 4-6 hours as needed
Anxiety, sedation, and procedural amnesia (unlabeled in children except for oral use in children >12 years):
Infants and Children:
Oral, I.M.: Usual: 0.05 mg/kg/dose (range: 0.02-0.09 mg/kg) every 4-8 hours
I.V.: Usual: 0.05 mg/kg/dose (range: 0.02-0.09 mg/kg) every 4-8 hours; may use smaller doses (eg, 0.01-0.03 mg/kg) and repeat every 20 minutes, as needed to titrate to effect
Adults:
Oral: 1-10 mg/day in 2-3 divided doses; usual dose: 2-6 mg/day in divided doses or 1-2 mg 1 hour before procedure
I.M.: 0.05 mg/kg administered 2 hours before surgery (maximum: 4 mg/dose)
I.V.: 0.044 mg/kg 15-20 minutes before surgery (usual dose 2 mg; maximum: 4 mg/dose)
Elderly: Oral: Initial: 1-2 mg/day in divided doses; Beers Criteria: Avoid maintenance doses >3 mg/day
Insomnia: Adults: Oral: 2-4 mg at bedtime
Status epilepticus: I.V.:
Infants and Children (unlabeled): 0.05-0.1 mg/kg (maximum: 4 mg/dose) slow I.V. (maximum rate: 2 mg/minute); may repeat every 10-15 minutes as needed (Hegenbarth, 2008; Sabo-Graham, 1998)
Adults: 4 mg/dose slow I.V. (maximum rate: 2 mg/minute); may repeat in 10-15 minutes; usual maximum dose: 8 mg. May be given I.M, but I.V. preferred.
Rapid tranquilization of agitated patient (unlabeled use): Adults: Oral, I.M.: 1-2 mg administered every 30-60 minutes; may be administered with an antipsychotic (eg, haloperidol) (Battaglia, 2005; De Fruyt, 2004)
Average total dose for tranquilization: 4-8 mg
Agitation in the ICU patient (unlabeled): Adults:
I.V.: 0.02-0.06 mg/kg every 2-6 hours or 0.01-0.1 mg/kg/hour (Jacobi, 2002)
Dosage adjustment for lorazepam with concomitant medications: Probenecid or valproic acid: Reduce lorazepam dose by 50%
Alcohol withdrawal syndrome (unlabeled use): Oral: 2 mg every 6 hours for 4 doses, then 1 mg every 6 hours for 8 additional doses (Mayo-Smith, 1997)
Alcohol withdrawal delirium (unlabeled use) (Mayo-Smith, 2004):
I.V.: 1-4 mg every 5-15 minutes until calm, then every hour as needed to maintain light somnolence
I.M.: 1-4 mg every 30-60 minutes until calm, then every hour as needed to maintain light somnolence
Dosage adjustment in renal impairment: I.V.: Risk of propylene glycol toxicity. Monitor closely if using for prolonged periods of time or at high doses.
Dosage adjustment in hepatic impairment: No dose reduction necessary.
Dental Usual Dosing
Anxiety and sedation: Adults: Oral: 1-10 mg/day in 2-3 divided doses; usual dose: 2-6 mg/day in divided doses
Preoperative: Adults:
I.M.: 0.05 mg/kg administered 2 hours before surgery (maximum: 4 mg/dose)
I.V.: 0.044 mg/kg 15-20 minutes before surgery (usual maximum: 2 mg/dose)
Preprocedural anxiety: Adults: Oral: 1-2 mg 1 hour before procedure
Administration: I.M.
Should be administered deep into the muscle mass.
Administration: I.V.
Continuous infusion solutions should have an in-line filter and the solution should be checked frequently for possible precipitation. Avoid intra-arterial administration. Monitor I.V. site for extravasation.
Administration: I.V. Detail
Dilute I.V. dose with equal volume of compatible diluent (D5W, NS, SWFI).
Monitoring Parameters
Respiratory and cardiovascular status, blood pressure, heart rate, symptoms of anxiety
Clinical signs of propylene glycol toxicity (for continuous high-dose and/or long duration intravenous use): Serum creatinine, BUN, serum lactate, osmol gap
Reference Range
Therapeutic: 50-240 ng/mL (SI: 156-746 nmol/L)
Patient Education
Oral: Drug may cause physical and/or psychological dependence. Do not use alcohol. You may experience drowsiness, lightheadedness, impaired coordination, dizziness, blurred vision, nausea, vomiting, dry mouth, constipation, altered sexual drive or ability (reversible), or photosensitivity. Report persistent CNS effects (eg, confusion, depression, increased sedation, excitation, headache, agitation, insomnia or nightmares, dizziness, fatigue, impaired coordination, changes in personality, or changes in cognition); changes in urinary pattern; chest pain, palpitations, or rapid heartbeat; muscle cramping, weakness, tremors, or rigidity; ringing in ears or visual disturbances; excessive perspiration; excessive GI symptoms (cramping, constipation, vomiting, anorexia); or worsening of condition.
Geriatric Considerations
Because lorazepam is relatively short-acting with an inactive metabolite, it is a preferred agent to use in elderly patients when a benzodiazepine is indicated.
This medication is considered to be potentially inappropriate in this patient population (Beers Criteria severity: High).
Additional Information
Oral doses >0.09 mg/kg produced increased ataxia without increased sedative benefit vs lower doses; preferred anxiolytic when I.M. route needed. Abrupt discontinuation after sustained use (generally >10 days) may cause withdrawal symptoms.
Anesthesia and Critical Care Concerns/Other Considerations
Lorazepam 2 mg/mL and 4 mg/mL each contain propylene glycol 830 mg/mL (80% v/v). In addition, lorazepam 2 mg/mL oral solution (Intensol™) contains propylene glycol.
Agitation in the ICU Patient: Lorazepam has a slower onset of action than midazolam or diazepam, making it less useful for treatment of acute agitation. The polyethylene glycol and propylene glycol solvents in lorazepam injection can accumulate and lead to reversible acute tubular necrosis, lactic acidosis, and hyperosmolar states with prolonged, high-dose infusions.
A prospective, observational study was performed in a medical intensive care unit evaluating patients receiving high-dose lorazepam (≥10 mg/hour) infusions (Arroliga, 2004). The primary objective was to evaluate the relationship between high-dose lorazepam and serum propylene glycol concentrations. Nine patients met the criteria for entry. Baseline creatinine clearances were 50-100 mL/minute. Propylene glycol accumulation was observed in these patients receiving high-dose lorazepam infusions for ≥48 hours. A significant correlation between high-dose lorazepam infusion rate and serum propylene glycol concentrations was observed. However, osmol gap was the strongest predictor (R2 = 0.80) of serum propylene glycol concentrations. Study findings suggest that in critically ill adults with normal renal function, serum propylene glycol concentrations may be predicted by the osmol gap. Based on these findings, propylene glycol accumulation may occur as early as 48 hours when using high-dose lorazepam infusions.
To calculate osmolarity: [2 x sodium (mEq/L)] + [glucose (mg/dL)/18] + [BUN (mg/dL)/2.8]
To calculate osmol gap (normal range: 0-5): (measured osmolality minus calculated osmolarity)
However, Nelsen et al (2008) conducted a prospective evaluation of 50 adult critically ill patients (median APACHE II = 20) receiving lorazepam continuous infusion for ≥48 hours in the surgical, medical or burn/trauma ICU. Eight patients exhibited PG accumulation (>25 mg/dL) associated with a median lorazepam infusion rate of 6.4 mg/hour, despite lack of correlation with osmolal gap or serum lactate levels. Of note, reduced clearance of PG correlated with increasing APACHE II scores.
Lorazepam is recommended for the sedation of most patients. Use a defined endpoint in titration of the dose. Use a system to minimize prolonged sedative effects. If patient has received high-dose or >7 days of continuous therapy, consider tapering infusion to prevent withdrawal symptoms.
In the MENDS trial, compared to dexmedetomidine the use of lorazepam for ICU sedation of mechanically-ventilated patients increased the number of days alive with delirium or coma. A nonsignificant increase in 28-day mortality was noted in the lorazepam group when compared to dexmedetomidine (27% vs 17%, respectively; p=0.18) (Pandharipande, 2007).
Cardiovascular Considerations
Hypotension may result in orthostatic lightheadedness or syncope. Benzodiazepines, as a class, may depress respiration. These medications may often be prescribed for difficulty in sleeping but may exacerbate sleep-disordered breathing.
Dental Health: Effects on Dental Treatment
Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation).
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
No information available to require special precautions
Mental Health: Comment
In 2007, the FDA requested that all manufacturers of sedative-hypnotic drug products revise labeling to include a greater emphasis on the risks of adverse effects. These risks include severe allergic reactions (anaphylaxis, angioedema) and complex sleep-related behaviors, which may include sleep-driving (driving while not fully awake and with no memory of the event), making phone calls, and preparing and eating food while asleep.
There are two subtypes of GABA receptors (GABA-A and GABA-B) and three different benzodiazepine receptors (Bz1, Bz2, and Bz3). Benzodiazepine receptors and effects appear to be linked to the GABA-A receptors. Benzodiazepines do not bind to GABA-B receptors. The role of GABA-B receptors is unclear. Benzodiazepines have no specificity for benzodiazepine receptor subtypes.
Lorazepam is a short half-life benzodiazepine. Duration of action after a single dose is determined by redistribution rather than metabolism. Tolerance develops to the sedative, hypnotic, and anticonvulsant effects. It does not develop to the anxiolytic or skeletal muscle relaxing effects. Psychological and physical dependence may occur with prolonged use of benzodiazepines. The onset of withdrawal symptoms is usually seen on the first day without drug and lasts 5-7 days in patients receiving short half-life benzodiazepines, whereas, the onset occurs after 5 days with a duration of 10-14 days after abrupt discontinuance of long half-life benzodiazepines. Risk factors for abuse include personal or family history of substance abuse and personality disorder.
Lorazepam is rapidly and completely absorbed after I.M. injection; undergoes phase II metabolism and, therefore, is less likely to be affected in patients with hepatic dysfunction.
Nursing: Physical Assessment/Monitoring
Oral: Assess for history of addiction; long-term use can result in dependence, abuse, or tolerance; periodically evaluate need for continued use. For inpatient use, institute safety measures to prevent falls. Taper dosage slowly when discontinuing. I.V./I.M.: Monitor vital signs, CNS status, and ability to void.
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Injection, solution: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL)
Ativan®: 2 mg/mL (1 mL, 10 mL); 4 mg/mL (1 mL, 10 mL) [contains benzyl alcohol, polyethylene glycol 400, propylene glycol]
Injection, solution [preservative free]: 2 mg/mL (1 mL [DSC]); 4 mg/mL (1 mL [DSC])
Solution, oral [concentrate]: 2 mg/mL (30 mL)
Lorazepam Intensol™: 2 mg/mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol]
Tablet, oral: 0.5 mg, 1 mg, 2 mg
Ativan®: 0.5 mg
Ativan®: 1 mg, 2 mg [scored]
Pricing: U.S. (www.drugstore.com)
Concentrate (LORazepam Intensol)
2 mg/mL (30): $44.99
Tablets (Ativan)
0.5 mg (30): $91.19
1 mg (30): $122.39
2 mg (30): $194.38
Tablets (LORazepam)
0.5 mg (30): $14.99
Tablets (Lorazepam)
1 mg (30): $14.99
Tablets (LORazepam)
2 mg (30): $21.99
Extemporaneously Prepared
Note: Commercial oral solution is available (2 mg/mL)
Two different 1 mg/mL oral suspensions may be made from different generic lorazepam tablets (Mylan Pharmaceuticals or Watson Laboratories), sterile water, Ora-Sweet®, and Ora-Plus®.
Mylan tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 144 mL of sterile water to disperse the tablets; shake until slurry is formed. Add 108 mL Ora-Plus® in incremental proportions; then add a quantity of Ora-Sweet® sufficient to make 360 mL. Label "shake well" and "refrigerate". Stable for 91 days when stored in amber glass prescription bottles at room temperature or refrigerated (preferred).
Watson tablets: Place one-hundred-eighty 2 mg tablets in a 12-ounce amber glass bottle; add 48 mL sterile water to disperse the tablets; shake until slurry is formed. Add 156 mL of Ora-Plus® in incremental proportions; then add a quantity of Ora-Sweet® sufficient to make 360 mL. Label "shake well" and "refrigerate". Store in amber glass prescription bottles. Stable for 63 days at room temperature or 91 days refrigerated.
Lee ME, Lugo RA, Rusho WJ, et al, "Chemical Stability of Extemporaneously Prepared Lorazepam Suspension at Two Temperatures," J Pediatr Pharmacol Ther, 2004, 9(4):254-58.
References
Abernethy DR, Greenblatt DJ, Ameer B, et al, “Probenecid Impairment of Acetaminophen and Lorazepam Clearance: Direct Inhibition of Ether Glucuronide Formation,” J Pharmacol Exp Ther, 1985, 234(2):345-9.
Alldredge BK, Gelb AM, Isaacs SM, et al, “A Comparison of Lorazepam, Diazepam, and Placebo for the Treatment of Out-of-Hospital Status Epilepticus,” N Engl J Med, 2001, 345(9):631-7.
Ameer B and Greenblatt DJ, “Lorazepam: A Review of Its Clinical Pharmacological Properties and Therapeutic Uses,” Drugs, 1981, 21(3):162-200.
American Academy of Pediatrics Committee on Drugs, "Transfer of Drugs and Other Chemicals Into Human Milk,” Pediatrics, 2001, 108(3):776-89.
Anderson GD, Gidal BE, Kantor ED, et al, “Lorazepam-Valproate Interaction: Studies in Normal Subjects and Isolated Perfused Rat Liver,” Epilepsia, 1994, 35(1):221-5.
Arroliga AC, Shehab N, McCarthy K, et al, “Relationship of Continuous Infusion Lorazepam to Serum Propylene Glycol Concentration in Critically Ill Adults,” Crit Care Med, 2004, 32(8):1709-14.
Barnes BJ, Gerst C, Smith JR, et al, “Osmol Gap as a Surrogate Marker for Serum Propylene Glycol Concentrations in Patients Receiving Lorazepam for Sedation,” Pharmacotherapy, 2006, 26(1):23-33.
Battaglia J, "Pharmacological Management of Acute Agitation," Drugs, 2005, 65(9):1207-22.
Bergman U, Rosa FW, Baum C, et al, "Effects of Exposure to Benzodiazepine During Fetal Life," Lancet, 1992, 340(8821):694-6.
Bishop JF, Olver IN, Wolf MM, et al, “Lorazepam: A Randomized, Double-Blind, Crossover Study of a New Antiemetic in Patients Receiving Cytotoxic Chemotherapy and Prochlorperazine,” J Clin Oncol, 1984, 2(5):691-5.
Bleck TB, Seizures, Stroke, and Other Neurologic Emergencies. In: Zimmerman JL, Roberts PR, eds. Multidisciplinary Critical Care Review, Des Plains, IL: Society of Critical Care Medicine; 2003:325-34.
Buzdar AU, Esparza L, Natale R, et al, “Lorazepam-Enhancement of the Antiemetic Efficacy of Dexamethasone and Promethazine. A Placebo-Controlled Study,” Am J Clin Oncol, 1994, 17(5):417-21.
Clark RF, Sage TA, Tunget C, et al, “Delayed Onset Lorazepam Poisoning Successfully Reversed by Flumazenil in a Child: Case Report and Review of the Literature,” Pediatr Emerg Care, 1995, 11(1):32-4.
Crawford TO, Mitchell WG, and Snodgrass SR, “Lorazepam in Childhood Status Epilepticus and Serial Seizures: Effectiveness and Tachyphylaxis,” Neurology, 1987, 37(2):190-5.
De Fruyt J and Demyttenaere K, "Rapid Tranquilization: New Approaches in the Emergency Treatment of Behavioral Disturbances," Eur Psychiatry, 2004, 19(5):243-9.
Deshmukh A, Wittert W, Schnitzler E, et al, “Lorazepam in the Treatment of Refractory Neonatal Seizures: A Pilot Study,” Am J Dis Child, 1986, 140(10):1042-4.
Divoll M and Greenblatt DJ, “Effect of Age and Sex on Lorazepam Protein Binding,” J Pharm Pharmacol, 1982, 34(2):122-3.
Fraser AD and Bryan W, “Evaluation of the Abbott TDx® Serum Benzodiazepine Immunoassay for the Analysis of Lorazepam, Adinazolam, and N-Desmethyladinazolam,” J Anal Toxicol, 1995, 19(5):281-4.
Greenblatt DJ, Allen MD, Locniskar A, et al, “Lorazepam Kinetics in the Elderly,” Clin Pharmacol Ther, 1979, 26(1):103-13.
Guterman B, Sebastian P, and Sodha N, “Recovery From Alpha Coma After Lorazepam Overdose,” Clin Electroencephalogr, 1981, 12(4):205-8.
Hayman M, Seidl EC, Ali M, et al, “Acute Tubular Necrosis Associated With Propylene Glycol From Concomitant Administration of Intravenous Lorazepam and Trimethoprim-sulfamethoxazole,” Pharmacotherapy, 2003, 23(9):1190-4.
Hegenbarth MA and the American Academy of Pediatrics Committee on Drugs, “Preparing for Pediatric Emergencies: Drugs to Consider,” Pediatrics, 2008, 121(2):433-43.
Henry DW, Burwinkle JW, and Klutman NE, “Determination of Sedative and Amnestic Doses of Lorazepam in Children,” Clin Pharm, 1991, 10(8):625-9.
Iqbal MM, Sobhan T, Ryals T, et al, "Effects of Commonly Used Benzodiazepines on the Fetus, the Neonate, and the Nursing Infant," Psychiatr Serv, 2002, 53(1):39-49.
Jacobi J, Fraser GL, Coursin DB, et al, “Clinical Practice Guidelines for the Sustained Use of Sedatives and Analgesics in the Critically Ill Adult,” Crit Care Med, 2002, 30(1):119-41.
Kalviainen R, “Status Epilepticus Treatment Guidelines,” Epilepsia, 2007, 48(Suppl 8):99-102.
Lapierre YD and Labelle A, “Manic-Like Reaction Induced by Lorazepam Withdrawal,” Can J Psychiatry, 1987, 32(8):697-8.
Laszlo J, Clark RA, Hanson DC, et al, “Lorazepam in Cancer Patients Treated With Cisplatin: A Drug Having Antiemetic, Amnesic, and Anxiolytic Effects,” J Clin Oncol, 1985, 3(6):864-9.
Lee SA, Lee JK, Heo K, “Coma Probably Induced by Lorazepam-Valproate Interaction,” Seizure, 2002, 11(2):124-5.
Lee DS, Wong HA, and Knoppert DC, “Myoclonus Associated With Lorazepam Therapy in Very-Low-Birth-Weight Infants,” Biol Neonate, 1994, 66(6):311-5.
Lheureux P and Askenasi R, “Specific Treatment of Benzodiazepine Overdose,” Hum Toxicol, 1988, 7(2):165-70.
Malik IA, Khan WA, Qazilbash M, et al, “Clinical Efficacy of Lorazepam in Prophylaxis of Anticipatory, Acute, and Delayed Nausea and Vomiting Induced by High Doses of Cisplatin. A Prospective Randomized Trial,” Am J Clin Oncol, 1995, 18(2):170-5.
Manno EM, “New Management Strategies in the Treatment of Status Epilepticus,” Mayo Clin Proc, 2003, 78(4):508-18.
Marshall JD, Farrar HC, and Kearns GL, “Diarrhea Associated With Enteral Benzodiazepine Solutions,” J Pediatr, 1995, 126(4):657-9.
Mayo-Smith MF, "Pharmacological Management of Alcohol Withdrawal. A Meta-analysis and Evidence-Based Practice Guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal," JAMA, 1997, 278(2):144-51
Mayo-Smith MF, Beecher LH, Fischer TL, et al, "Management of Alcohol Withdrawal Delirium. An Evidence-Based Practice Guideline," Arch Intern Med, 2004, 164(13):1405-12; published erratum appears in Arch Intern Med, 2004, 164(18):2068.
McDermott CA, Kowalczyk AL, Schnitzler ER, et al, “Pharmacokinetics of Lorazepam in Critically Ill Neonates With Seizures,” J Pediatr, 1992, 120(3):479-83.
Mokhlesi B, Leikin JB, Murray P, et al, “Adult Toxicology in Critical Care: Part II: Specific Poisonings,” Chest, 2003, 123(3):897-922.
Nelsen JL, Haas, CE, Habtemariam B, et al, “A Prospective Evaluation of Propylene Glycol Clearance and Accumulation During Continuous-Infusion Lorazepam in Critically Ill Patients,” J Intens Care Med, 2008, 23(3):184-94.
Pandharipande PP, Pun BT, Herr DL, et al, “Effect of Sedation With Dexmedetomidine Vs Lorazepam on Acute Brain Dysfunction in Mechanically Ventilated Patients: The MENDS Randomized Controlled Trial,” JAMA, 2007, 298(22):2644-53.
Sabo-Graham T and Seay AR, “Management of Status Epilepticus in Children,” Pediatr Rev, 1998, 19(9):306-9.
Samara EE, Granneman RG, Witt GF, et al, “Effect of Valproate on the Pharmacokinetics and Pharmacodynamics of Lorazepam,” J Clin Pharmacol, 1997, 37(5):442-50.
Stanford GK and Pine RH, “Postburn Delirium Associated With Use of Intravenous Lorazepam,” J Burn Care Rehabil, 1988, 9(2):160-1.
“Treatment of Convulsive Status Epilepticus. Recommendations of the Epilepsy Foundation of America's Working Group on Status Epilepticus,” JAMA, 1993, 270(7):854-9.
Treiman DM, Meyers PD, Walton NY, et al, “A Comparison of Four Treatments for Generalized Convulsive Status Epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group,” N Engl J Med, 1998, 339(12):792-8.
Uchaipichat V, Mackenzie PI, Guo XH, et al, “Human UDP-Glucuronosyltransferases: Isoform Selectivity and Kinetics of 4-Methylumbelliferone and 1-Naphthol Glucuronidation, Effects of Organic Solvents, and Inhibition by Diclofenac and Probenecid,” Drug Metab Dispos, 2004, 32(4):413-23.
Vlachos P, Kentarchou P, Poulosa L, et al, “Lorazepam Poisoning,” Toxicol Lett, 1978, 2:109-10.
von Moltke LL, Manis M, Harmatz JS, et al, “Inhibition of Acetaminophen and Lorazepam Glucuronidation In Vitro by Probenecid,” Biopharm Drug Dispos, 1993, 14(2):119-30.
Wikner BN, Stiller CO, Bergman U, et al, "Use of Benzodiazepines and Benzodiazepine Receptor Agonists During Pregnancy: Neonatal Outcome and Congenital Malformations," Pharmacoepidemiol Drug Saf, 2007, 16(11):1203-10.
Wiley J and Wiley C, “Benzodiazepine Ingestions in Children,” Clin Toxicol, 1995, 33(5):520.
Yaucher NE, Fish JT, Smith HW, et al, “Propylene Glycol-Associated Renal Toxicity From Lorazepam Infusion,” Pharmacotherapy, 2003, 23(9):1094-9.
International Brand Names
Lexi-Comp.com
Last full review/revision February 2012
Content last modified February 2012
| 
